NEW YORK, NY / ACCESSWIRE / December 13, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with BioVie.

Toni had the pleasure of recently conducting the Interview with Cuong Do, President & CEO BioVie Inc. (NASDAQ:BIVI). Toni diligently focused on questions she thought would be on the minds of most current and potential future shareholders. See interview highlights below.

Access this interview in its entirety at https://tradersnewssource.com/bivi-interview/

Cuong Do

President & Chief Executive Officer​

Cuong Do, MBA, is President and CEO of BioVie Inc . Prior to his appointment with BioVie, Mr. Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for Samsung Group's diverse business portfolio. He was previously the Chief Strategy Officer for Merck, a leading US pharmaceuticals company. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years helping to build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.

Interview Highlights:

Traders News Source Editor Toni Loudenbeck and Cuong Do discuss an overview of the company, biotech pipeline, current clinical trial progress plus much more in this interview.

Access this interview in its entirety at https://tradersnewssource.com/bivi-interview/

About BioVie

BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028) and is targeting primary completion in mid-2023. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed and provided its topline data readout in December 2022. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis with top-line results anticipated in mid-2023. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/.

For Public/Press Relations Inquiries:

Dennis Consorte
(201) 344-9648
dennisconsorte@gmail.com

For Investor Relations Inquiries:

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

About Traders News Source (TNS)

Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit: https://tradersnewssource.com/bivi-interview/

Media Contact

Traders News Source

Mark Roberts, Senior Editor/Interviewer
Editor@TradersNewsSource.com

SOURCE: Traders News Source LLC